Back to News
Market Impact: 0.55

3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

IDXXNNOX
Company FundamentalsCorporate EarningsAnalyst EstimatesAnalyst InsightsCorporate Guidance & OutlookHealthcare & Biotech
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

Idexx Laboratories (IDXX) is identified as a strong growth stock, supported by a Zacks Growth Score of B and a Zacks Rank #2. Key factors include a projected 17.6% EPS growth for the current year, significantly exceeding the industry average of 14.8%, and a 6% year-over-year cash flow growth, contrasting with the industry's -2.5%. Additionally, positive earnings estimate revisions, with the Zacks Consensus Estimate for the current year rising 3.3% over the past month, further underscore IDXX's potential as an outperforming investment for growth-oriented portfolios.

Analysis

Idexx Laboratories (IDXX) is presented as a compelling growth stock, underpinned by a Zacks Rank #2 (Buy) and a 'B' grade for its Growth Score. The positive outlook is supported by several key fundamental metrics that suggest outperformance relative to its sector. The company's earnings per share (EPS) are projected to grow 17.6% this year, a figure that notably exceeds the industry average forecast of 14.8%. Furthermore, Idexx demonstrates robust liquidity and operational efficiency with a current year-over-year cash flow growth of 6%, which stands in stark contrast to the industry's average contraction of -2.5%. This strong current performance is built on a solid historical foundation, evidenced by a 3-5 year annualized cash flow growth rate of 14.6%. The bullish thesis is further reinforced by recent positive earnings estimate revisions, as the Zacks Consensus Estimate for the current year has increased by 3.3% in the last month, a strong indicator of improving analyst sentiment.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo